Authors from America present a comprehensive review of botulinum toxin A in the overactive bladder. The use of this agent in resistant cases is becoming more prevalent, and these authors have carried out an extensive literature search to establish its current status and other future directions that it might take. The other reviews concern urological cancer, two relating to prostate cancer and one to molecular targeting agents used in the treatment of metastatic RCC.
No takes yet. Share an insight, caveat, or question.
Dmochowski et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: